Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jul 31;5(3):2055217319864974.
doi: 10.1177/2055217319864974. eCollection 2019 Jul-Sep.

Efficacy of dimethyl fumarate in Japanese multiple sclerosis patients: interim analysis of randomized, double-blind APEX study and its open-label extension

T Kondo  1 , I Kawachi  2   3 , Y Onizuka, K Hiramatsu, M Hase  4 , J Yun  5 , A Matta  5 , S Torii  4
Affiliations

Efficacy of dimethyl fumarate in Japanese multiple sclerosis patients: interim analysis of randomized, double-blind APEX study and its open-label extension

T Kondo et al. Mult Scler J Exp Transl Clin. .

Abstract

Background: Current data for the use of dimethyl fumarate (DMF) in Japanese patients with relapsing-remitting multiple sclerosis (RRMS) is limited.

Objectives: To assess the efficacy of DMF in Japanese patients with RRMS.

Methods: The phase 3, multinational APEX study (ClinicalTrials.gov identifier: NCT01838668) consisted of two parts: a 24-week double-blind part where subjects were randomized to receive DMF 240 mg or placebo twice daily in East Asian and Eastern European countries, and an open-label extension part where all subjects received DMF. The primary endpoint was the total number of new gadolinium-enhancing lesions in Weeks 12-24. In this interim analysis, we report efficacy data in the Japanese subgroup (DMF n = 56; placebo n = 58) over 72 weeks, including an extension phase.

Results: DMF reduced the total number of new gadolinium-enhancing lesions in Weeks 12-24 by 85% versus placebo (p < 0.0001). At Week 24, the annualized relapse rate was also reduced by 48% with DMF, versus placebo. DMF reduced the probability of relapse from Week 8 and was sustained. The number of gadolinium-enhancing lesions was maintained through 72 weeks.

Conclusions: DMF demonstrated sustained efficacy in this Japanese subgroup. The results were consistent with those observed in studies of DMF enrolling primarily Caucasian patients.

Keywords: APEX; Japanese patients; delayed release; dimethyl fumarate; efficacy; relapsing–remitting multiple sclerosis.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
CONSORT diagram of the study design.
Figure 2.
Figure 2.
The number of new gadolinium-enhancing (Gd+) lesions at (a) Weeks 12–24 and (b) Weeks 0–24. CI, confidence interval; DMF, dimethyl fumarate.
Figure 3.
Figure 3.
Kaplan–Meier estimate of the probability of relapse in Parts I and II of the APEX study, up to Week 72, for Japanese subjects in placebo/dimethyl fumarate (DMF) and DMF/DMF groups.
Figure 4.
Figure 4.
Expanded Disability Status Scale (EDSS) of Japanese subjects over 72 weeks in both Parts I and II. DMF, dimethyl fumarate.
See this image and copyright information in PMC

References

    1. Nylander A, Hafler D. Multiple sclerosis. J Clin Invest 2012; 122: 1180--2. - PMC - PubMed
    1. WHO. Atlas: multiple sclerosis resources in the world 2008 World Health Organization, 2008.
    1. Houzen H, Kondo K, Horiuchi K, et al. Consistent increase in the prevalence and female ratio of multiple sclerosis over 15 years in northern Japan. Eur J Neurol 2018; 25: 334–339. - PubMed
    1. Nakashima I, Fukazawa T, Ota K, et al. Two subtypes of optic-spinal form of multiple sclerosis in Japan: clinical and laboratory features. J Neurol 2007; 254: 488–492. - PubMed
    1. Menge T, Weber MS, Hemmer B, et al. Disease-modifying agents for multiple sclerosis: recent advances and future prospects. Drugs 2008; 68: 2445–2468. - PubMed

Associated data

LinkOut - more resources